Literature DB >> 23638950

Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines.

Zainal Adhim1, Naoki Otsuki, Junko Kitamoto, Naoya Morishita, Masato Kawabata, Toshiro Shirakawa, Ken-Ichi Nibu.   

Abstract

CONCLUSION: Our results indicate that siRNA E6 and/or E7 may have potential as a gene-specific therapy for human papillomavirus (HPV) type 16 (HPV16)-related squamous cell carcinoma of the head and neck (HNSCC).
OBJECTIVES: To evaluate the effectiveness of siRNA targeting E6 and/or E7 on the in vitro and in vivo growth suppression of HPV16-related HNSCC.
METHODS: HPV16-related HNSCC (UM-SCC47) cell lines were used for the present study. Expression of HPV viral oncogenes E6 and/or E7 and their cellular targets, p53 and pRb, was evaluated by real-time PCR, Western blotting, and immunofluorescence staining. To study the effect of siRNA on tumor growth in vivo, we developed animal models. Representative tumors harvested from each group were processed for apoptosis analyses (TUNEL assay) and immunofluorescence staining for p53 and pRb.
RESULTS: E6 and E7 oncogenes of HPV16 were down-regulated by E6 and/or E7 targeting siRNAs, respectively. The expression of p53 and pRb proteins in both the E6 siRNA group and E7 siRNA group was up-regulated compared with those of control groups. The cellular proliferation and apoptosis indexes of E6 and/or E7 siRNA groups were higher than those of controls. In vivo studies showed significant inhibitory effect of E6 and/or E7 siRNA compared with those of control groups, which was consistent with in vitro studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23638950     DOI: 10.3109/00016489.2013.773405

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  6 in total

Review 1.  Therapeutic potential of siRNA and DNAzymes in cancer.

Authors:  Hanuma Kumar Karnati; Ravi Shekar Yalagala; Rambabu Undi; Satya Ratan Pasupuleti; Ravi Kumar Gutti
Journal:  Tumour Biol       Date:  2014-08-23

2.  Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Authors:  Ning Jiang; Dongsheng Wang; Zhongliang Hu; Hyung Ju C Shin; Guoqing Qian; Mohammad Aminur Rahman; Hongzheng Zhang; A R M Ruhul Amin; Sreenivas Nannapaneni; Xiaojing Wang; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Jun Ma; Zhuo G Chen; Nabil F Saba
Journal:  Mol Cancer Ther       Date:  2014-04-18       Impact factor: 6.261

3.  Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Authors:  Toni M Brand; Stefan Hartmann; Neil E Bhola; Hua Li; Yan Zeng; Rachel A O'Keefe; Max V Ranall; Sourav Bandyopadhyay; Margaret Soucheray; Nevan J Krogan; Carolyn Kemp; Umamaheswar Duvvuri; Theresa LaVallee; Daniel E Johnson; Michelle A Ozbun; Julie E Bauman; Jennifer R Grandis
Journal:  Cancer Res       Date:  2018-02-12       Impact factor: 13.312

4.  Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation.

Authors:  Fei Zhao; Weiwei Huang; Tamgue Ousman; Bin Zhang; Yangyang Han; Daguia Zambe John Clotaire; Chen Wang; Huanhuan Chang; Huanan Luo; Xiaoyong Ren; Ming Lei
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

5.  GSK3β mediates the carcinogenic effect of HPV16 in cervical cancer.

Authors:  Cuiling Ma; Chenglong Zeng; Liang Jin; Yang Yang; Pengfei Li; Liangfeng Chen; Jian Wang
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

6.  Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.

Authors:  Naoto Sato; Yasushi Saga; Ryosuke Uchibori; Tomonori Tsukahara; Masashi Urabe; Akihiro Kume; Hiroyuki Fujiwara; Mitsuaki Suzuki; Keiya Ozawa; Hiroaki Mizukami
Journal:  Int J Oncol       Date:  2018-01-15       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.